PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

ValueSet: Risk Factors

Official URL: http://hl7.eu/fhir/ig/pcsp/ValueSet/vs-riskfactor-eu-pcsp Version: 1.0.0
Active as of 2025-10-16 Computable Name: RiskFactor

Risk Factors used by the PCSP algorithm

References

Logical Definition (CLD)

 

Expansion

Expansion performed internally based on codesystem Risk Factors v1.0.0 (CodeSystem)

This value set contains 112 concepts

SystemCodeDisplay (en)JSONXML
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  1.1RT to a vol exposing the thyroid gland
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  1.2TBI
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  1.3MIBG therapy (I-131 MIBG therapy)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  2.1RT >= 10 Gy to a vol exposing the breasts
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  2.2OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  3.1RT >= 35 Gy to a vol exposing the heart
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  3.2Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  3.3RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  4.1Alkylating agents
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  4.2RT to a vol exposing the testes
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  4.3Including TBI
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  5.1RT >=12 Gy to a vol exposing the testicles
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  6.3Surgery to the spinal cord, sympathetic nerves or pelvis
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  6.4Hypogonadal
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  7.2RT to a vol exposing the ovaries
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  8.1RT >= 30 Gy to a vol exposing the head or the brain
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  8.2Cisplatin (with or without carboplatin > 1500 mg/m2)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  9.1RT to a vol exposing the pancreas
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  10.2HSCT
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  11.1RT to a volume exposing the hypothalamus or pituatary gland
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  11.3Hypothalamic or pituitary tumour
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  11.4Neurosurgery of the hypothalamus or pituitary gland
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  12.1RT to a vol exposing the kidneys, heart and associated large vessels
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  12.3Nephrectomy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  12.4Ifosfamide
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  12.5Platinium based chemotherapy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  12.6Nitrosureas
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  12.7Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  13.1Cranial and/or spinal RT
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  13.3Methotrexate
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  13.4Gonadal failure
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  13.5Growth hormone deficiency
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  13.6Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  13.7HSCT, especially with an history of GVHD
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  14.3High dose RT
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  15.1Radiotherapy to a vol exposing the HP region >= 30 Gy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  15.2Surgery near or within the HP region
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  15.3CNS tumours near or within the HP region
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  16.1Radiotherapy to a vol exposing the HP region< 30 Gy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  16.2Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  17.1Radiotherapy to a vol exposing the HP region
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  17.5hydrocephalus or cerebrospinal fluid shunt
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  19.3Radioiodine therapy (I-131 ablation therapy)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  19.5Allogenic HSCT
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  19.6Total thyroidectomy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  20.1RT to a vol exposing the head, brain or neck
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  21.1History of a central nervous system tumor
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  21.2RT to a vol exposing the brain ANY DOSE
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  21.4Brain surgery
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  21.5High dose cytarabine IV (intravenous)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  21.6High dose MTX IV
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  21.7Any Chemotherapy IT (intrathecal)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  22.1Vinca-Alkaloids
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  22.2Cisplatin or carboplatin
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  23.1RT to a vol exposing the lens
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  24.1RT to a vol exposing the eye and orbit
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  25.1RT to a vol exposing the craniofacial area, especially after high doses and at a young age
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  25.3Surgery to the face, especially at a young age
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  26.1Surgery of the spine
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  26.2Surgery of the chest (Does not include CVC pose)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  26.3RT to a vol exposing the spine
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  26.4Spinal or paraspinal malignancies
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  27.1Cyclophosphamide
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  27.3RT to a vol exposing the bladder
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  27.5Cystectomy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  27.6Hysterectomy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  27.7Pelvic surgery
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  27.8Spinal cord surgery
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  28.1RT to a vol exposing the uterus only female
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  29.1RT to a vol exposing the oral cavity or salivary glands
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  29.4Chemotherapy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  30.1RT to a vol exposing the gastro-intestinal tract
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  30.3Oesophageal surgery
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  30.4Abdominal surgery
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  30.5With a history of chronic GVHD
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  31.1Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  32.1RT to a vol exposing the lungs
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  32.3Bleomycin
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  32.4Busulfan
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  32.5BCNU Carmustine
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  32.6CCNU Lomustine
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  32.7Thoracic surgery
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  33.1Cisplatin Any dose
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  33.2Ifosfamide Any dose
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  33.3Carboplatin Any dose
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.1RT to a volume exposing the liver
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.10Chronic GVHD
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.11Liver surgery
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.3HSCT (irrespective of GVHD)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.5Mercaptopurine Thioguanine
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.6Dactinomycin
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.8Chronic viral hepatitis
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  34.9Sinusoidal obstruction syndrome
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  35.1HSCT (irrespective of GVHD)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  35.2Multiple red blood cell transfusions
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  36.1Splenectomy
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  36.2RT >= 10 Gy to a vol exposing the spleen
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  36.3Allogenic HSCT (with or without TBI)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  36.4Autologus HSCT conditioned with TBI
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  37.1Hereditary cancer sd
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  38.1Any RT including TBI (predominantly in the RT field)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  38.2HSCT Especially with a history of skin GvHD
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  39.1RT to a vol exposing the colon and rectum
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  40.1RT to a vol exposing the oral cavity
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  41.2Anthracyclines and/or Mitoxantrone
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  41.3Epipodophyllotoxins or autologous
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  41.4Autologous haematopoietic stem cell transplant
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  42.1Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  45.1RT to a vol exposing the head or brain
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  46.1RT between 15 and 35 Gy to a vol exposing the heart
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  46.2Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp  47.1RT to a vol exposing the kidney or urinary tract

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code